{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:36:49Z","timestamp":1794746209065,"version":"4.9.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment with exogenous alpha-1 antitrypsin (AAT), a potent serine protease inhibitor, was developed originally for chronic obstructive pulmonary disease associated with AAT deficiency; however, other lung conditions involving neutrophilic inflammation and proteolytic tissue injury related to neutrophil elastase and other serine proteases may also be considered for AAT therapy. These conditions include bronchiectasis caused by primary ciliary dyskinesia, cystic fibrosis, and other diseases associated with an increased free elastase activity in the airways. Inhaled AAT may be a viable option to counteract proteolytic tissue damage. This form of treatment requires efficient drug delivery to the targeted pulmonary compartment. Aerosol technology meeting this requirement is currently available and offers an alternative therapeutic approach to systemic AAT administration. To date, early studies in humans have shown biochemical efficacy and have established the safety of inhaled AAT. However, to bring aerosol AAT therapy to patients, large phase 3 protocols in carefully selected patient populations (i.e., subgroups of patients with AAT deficiency, cystic fibrosis, or other lung diseases with bronchiectasis) will be needed with clinical end points in addition to the measurement of proteolytic activity in the airway. The outcomes likely will have to include lung function, lung structure assessed by computed tomography imaging, disease exacerbations, health status, and mortality.<\/jats:p>","DOI":"10.1513\/annalsats.201507-469kv","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T13:23:11Z","timestamp":1472217791000},"page":"S346-S351","source":"Crossref","is-referenced-by-count":28,"title":["Delivery of Alpha-1 Antitrypsin to Airways"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0113-912X","authenticated-orcid":false,"given":"Matthias","family":"Griese","sequence":"first","affiliation":[{"name":"Department of Pediatric Pneumology, Hauner Children\u2019s Hospital, University of Munich, German Center for Lung Research, Munich, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Scheuch","sequence":"additional","affiliation":[{"name":"Bio-Inhalation GmbH, Gem\u00fcnden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"2026020402535602500_bib1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm1690","article-title":"Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease","volume":"13","author":"Hartl","year":"2007","journal-title":"Nat Med"},{"key":"2026020402535602500_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1183\/09031936.00047306","article-title":"alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients","volume":"29","author":"Griese","year":"2007","journal-title":"Eur Respir J"},{"key":"2026020402535602500_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/1522-2683(200101)22:1<165::AID-ELPS165>3.0.CO;2-H","article-title":"Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis","volume":"22","author":"Griese","year":"2001","journal-title":"Electrophoresis"},{"key":"2026020402535602500_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/pupt.2001.0317","article-title":"Inhalation of alpha(1)-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity","volume":"14","author":"Griese","year":"2001","journal-title":"Pulm Pharmacol Ther"},{"key":"2026020402535602500_bib5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1476-5381.2009.00448.x","article-title":"Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery","volume":"158","author":"Greene","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2026020402535602500_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1164\/rccm.200703-489OC","article-title":"Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency","volume":"176","author":"Parr","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020402535602500_bib7","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"2026020402535602500_bib8","first-page":"547","article-title":"Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies","volume-title":"BioDrugs","author":"Turner","year":"2013"},{"key":"2026020402535602500_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1183\/09031936.00029809","article-title":"Intravenous alpha1-antitrypsin in a child with deficiency and severe lung disease","volume":"34","author":"Griese","year":"2009","journal-title":"Eur Respir J"},{"key":"2026020402535602500_bib10","first-page":"131","article-title":"Inhalation drug delivery devices: technology update","volume":"8","author":"Ibrahim","year":"2015","journal-title":"Med Devices (Auckl)"},{"key":"2026020402535602500_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4155\/tde.14.3","article-title":"The PulmoSphere\u2122 platform for pulmonary drug delivery","volume":"5","author":"Weers","year":"2014","journal-title":"Ther Deliv"},{"key":"2026020402535602500_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere\u2122 technology","volume":"24","author":"Geller","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026020402535602500_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/jamp.2012.0973","article-title":"Dose emission characteristics of placebo PulmoSphere\u00ae particles are unaffected by a subject\u2019s inhalation maneuver","volume":"26","author":"Weers","year":"2013","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026020402535602500_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2014.10.003","article-title":"Protein stability in pulmonary drug delivery via nebulization","volume":"93","author":"Hertel","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"2026020402535602500_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2047-783X-14-S4-71","article-title":"Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials","volume":"14","author":"Fischer","year":"2009","journal-title":"Eur J Med Res"},{"key":"2026020402535602500_bib16","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1089\/jamp.2009.0793","article-title":"The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation","volume":"23","author":"Geller","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026020402535602500_bib17","first-page":"386","article-title":"Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method","volume-title":"Eur J Pharm Biopharm","author":"Hertel","year":"2014"},{"key":"2026020402535602500_bib18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1172\/JCI114305","article-title":"Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency","volume":"84","author":"Hubbard","year":"1989","journal-title":"J Clin Invest"},{"key":"2026020402535602500_bib19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1073\/pnas.86.2.680","article-title":"Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance","volume":"86","author":"Hubbard","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020402535602500_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7326\/0003-4819-111-3-206","article-title":"Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin","volume":"111","author":"Hubbard","year":"1989","journal-title":"Ann Intern Med"},{"key":"2026020402535602500_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1183\/09031936.00118408","article-title":"Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency","volume":"34","author":"Brand","year":"2009","journal-title":"Eur Respir J"},{"key":"2026020402535602500_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.rmed.2015.01.022","article-title":"SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency","volume":"109","author":"Sorrells","year":"2015","journal-title":"Respir Med"},{"key":"2026020402535602500_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.00146807","article-title":"Inhibition of airway proteases in cystic fibrosis lung disease","volume":"32","author":"Griese","year":"2008","journal-title":"Eur Respir J"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/Supplement_4\/S346\/66667347\/annalsats_13_supplement_4_s346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/13\/Supplement_4\/S346\/66667347\/annalsats_13_supplement_4_s346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:54:05Z","timestamp":1770191645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/13\/Supplement_4\/S346\/8449165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":23,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2016,8,1]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201507-469kv","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,8]]},"published":{"date-parts":[[2016,8,1]]}}}